OLN OLIN Corp
Chemicals & Allied Products · NYSE · SEC CIK 74303 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-0.7%
TTM net income YoY-531.2%
TTM EPS YoY-519.1%
Revenue 3-yr CAGR-2.2%
Net income 3-yr CAGR—
Margins
Gross margin6.7%
Operating margin-1.9%
Net margin-3.3%
FCF margin3.3%
EBITDA margin5.2%
Returns
ROE-12.2%
ROA-3.0%
ROIC (approx.)-2.2%
Asset turnover0.90x
Leverage & solvency
Liabilities / assets76.8%
Debt / equity1.75x
Current ratio1.45x
Interest coverage-0.71x
Cash quality & payout
Operating cash flow / net income-1.74x
Accruals ratio-8.2%
Payout ratio—
Capex / revenue2.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $6.78B | $6.54B | $6.83B | $9.38B | $8.91B |
| Cost of revenue | $6.28B | $5.80B | $5.67B | $7.19B | $6.62B |
| Gross profit | $501.50M | $737.50M | $1.17B | $2.18B | $2.29B |
| SG&A expense | $463.30M | $408.50M | $406.70M | $393.90M | $416.90M |
| Operating income | $5.30M | $296.50M | $712.10M | $1.78B | $1.85B |
| Interest expense | $188.30M | $184.50M | $181.10M | $143.90M | $348.00M |
| Pretax income | -$161.10M | $141.70M | $559.30M | $1.68B | $1.54B |
| Income tax | -$60.00M | $36.70M | $107.30M | $349.10M | $242.00M |
| Net income | -$101.10M | $105.00M | $452.00M | $1.33B | $1.30B |
| EBITDA | $526.90M | $814.60M | $1.25B | $2.38B | $2.43B |
| EPS (basic) | -0.88 | 0.92 | 3.66 | 9.16 | 8.15 |
| EPS (diluted) | -0.88 | 0.91 | 3.57 | 8.94 | 7.96 |
| Weighted avg. shares (diluted) | 114.60M | 119.50M | 128.80M | 148.50M | 163.00M |
| Balance sheet | |||||
| Cash & equivalents | $167.60M | $175.60M | $170.30M | $194.00M | $180.50M |
| Short-term investments | $0 | $0 | $0 | $0 | $0 |
| Inventory | $784.50M | $823.50M | $858.80M | $941.90M | $868.30M |
| Current assets | $1.97B | $2.08B | $1.97B | $2.16B | $2.25B |
| PP&E, net | $2.20B | $2.33B | $2.52B | $2.67B | $2.91B |
| Goodwill | $1.43B | $1.42B | $1.42B | $1.42B | $1.42B |
| Intangibles | $174.40M | $206.60M | $245.80M | $273.80M | $331.70M |
| Total assets | $7.33B | $7.58B | $7.71B | $8.04B | $8.52B |
| Current liabilities | $1.63B | $1.63B | $1.53B | $1.56B | $1.68B |
| Short-term debt | $109.70M | $129.00M | $78.80M | $9.70M | $201.10M |
| Long-term debt | $2.72B | $2.71B | $2.59B | $2.57B | $2.58B |
| Total debt | $2.83B | $2.84B | $2.67B | $2.58B | $2.78B |
| Total liabilities | $5.46B | $5.52B | $5.44B | $5.50B | $5.87B |
| Shareholders' equity | $1.84B | $2.02B | $2.23B | $2.54B | $2.65B |
| Net debt | $2.66B | $2.67B | $2.50B | $2.39B | $2.60B |
| Shares outstanding | 113.60M | 115.70M | 120.20M | 132.30M | 156.80M |
| Cash flow statement | |||||
| Operating cash flow | $474.20M | $503.20M | $974.30M | $1.92B | $1.74B |
| Capital expenditure | $226.30M | $195.10M | $236.00M | $236.90M | $200.60M |
| Free cash flow | $247.90M | $308.10M | $738.30M | $1.69B | $1.54B |
| Investing cash flow | -$319.60M | -$283.70M | -$340.80M | -$259.70M | -$197.40M |
| Financing cash flow | -$163.00M | -$212.60M | -$656.90M | -$1.65B | -$1.55B |
| Depreciation & amortization | $521.60M | $518.10M | $533.40M | $598.80M | $582.50M |
| Stock-based compensation | $20.70M | $17.10M | $18.60M | $14.10M | $8.30M |
| Dividends paid | $91.60M | $94.20M | $101.00M | $116.20M | $127.80M |
| Share buybacks | $50.50M | $300.30M | $711.30M | $1.35B | $251.90M |
Free plan shows the latest 5 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.